Advanced Biomed Statistics
Total Valuation
Advanced Biomed has a market cap or net worth of $2.73 million. The enterprise value is $2.55 million.
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Advanced Biomed has 1.65 million shares outstanding. The number of shares has increased by 33.29% in one year.
| Current Share Class | 1.65M |
| Shares Outstanding | 1.65M |
| Shares Change (YoY) | +33.29% |
| Shares Change (QoQ) | +5.57% |
| Owned by Insiders (%) | 40.30% |
| Owned by Institutions (%) | 6.47% |
| Float | 986,283 |
Valuation Ratios
The trailing PE ratio is 0.38.
| PE Ratio | 0.38 |
| Forward PE | n/a |
| PS Ratio | 21.36 |
| Forward PS | n/a |
| PB Ratio | 0.24 |
| P/TBV Ratio | 0.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | 0.42 |
| EV / Sales | 19.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.09, with a Debt / Equity ratio of 0.00.
| Current Ratio | 8.09 |
| Quick Ratio | 8.09 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -318.94 |
Financial Efficiency
Return on equity (ROE) is -99.40% and return on invested capital (ROIC) is -55.06%.
| Return on Equity (ROE) | -99.40% |
| Return on Assets (ROA) | -46.10% |
| Return on Invested Capital (ROIC) | -55.06% |
| Return on Capital Employed (ROCE) | -62.42% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $10,636 |
| Profits Per Employee | $506,244 |
| Employee Count | 12 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1,205 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.04% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -80.04% |
| 50-Day Moving Average | 4.43 |
| 200-Day Moving Average | 5.64 |
| Relative Strength Index (RSI) | 31.90 |
| Average Volume (20 Days) | 73,534 |
Short Selling Information
The latest short interest is 11,238, so 0.68% of the outstanding shares have been sold short.
| Short Interest | 11,238 |
| Short Previous Month | 9,747 |
| Short % of Shares Out | 0.68% |
| Short % of Float | 1.14% |
| Short Ratio (days to cover) | 0.31 |
Income Statement
In the last 12 months, Advanced Biomed had revenue of $127,637 and earned $6.07 million in profits. Earnings per share was $4.35.
| Revenue | 127,637 |
| Gross Profit | 127,637 |
| Operating Income | -7.06M |
| Pretax Income | -7.10M |
| Net Income | 6.07M |
| EBITDA | n/a |
| EBIT | -7.06M |
| Earnings Per Share (EPS) | $4.35 |
Full Income Statement Balance Sheet
The company has $213,995 in cash and $33,477 in debt, with a net cash position of $180,518 or $0.11 per share.
| Cash & Cash Equivalents | 213,995 |
| Total Debt | 33,477 |
| Net Cash | 180,518 |
| Net Cash Per Share | $0.11 |
| Equity (Book Value) | 11.29M |
| Book Value Per Share | 6.83 |
| Working Capital | 11.28M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -1.51M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 917,989 |
| Free Cash Flow | -1.51M |
| FCF Per Share | -$0.91 |
Full Cash Flow Statement Margins
Gross margin is 100.00%, with operating and profit margins of -5,531.56% and 4,759.53%.
| Gross Margin | 100.00% |
| Operating Margin | -5,531.56% |
| Pretax Margin | -5,566.08% |
| Profit Margin | 4,759.53% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Advanced Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -33.29% |
| Shareholder Yield | -33.29% |
| Earnings Yield | 263.88% |
| FCF Yield | -55.32% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on February 20, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Feb 20, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Advanced Biomed has an Altman Z-Score of 1.2 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.2 |
| Piotroski F-Score | 2 |